ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

Von Eschenbach Presents His “2015 Goal” As Logical Progression of Cancer Program (Interview)

May 16, 2003

Trapido To Lead NCI’s Epidemiology Program.

July 26, 2002

Most Comprehensive Centers Getting Core Grants Renewed

July 27, 1990

President’s Cancer Panel Special Commission On Breast Cancer Named

April 25, 1992

Clinical Trials Approved By NCI CTEP Last Month

May 27, 2011

Tobacco Council Awards 34 New Grants

April 16, 1982